| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | budesonide / formoterol (DuoResp Spiromax®) |
| Formulation | 160 micrograms / 4.5 micrograms and 320 micrograms / 9 micrograms |
| Reference number | 4914 |
| Indication | In adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists; or in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists |
| Company | TEVA UK Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 02/12/2021 |